# Abatacept in Immune Checkpoint Inhibitor Myocarditis

> **NCT05335928** · PHASE3 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 390 (estimated)

## Conditions studied

- Myocarditis Acute
- Cancer

## Interventions

- **DRUG:** Abatacept plus
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05335928
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-02
- **Primary completion:** 2026-11-20
- **Final completion:** 2027-04-20
- **Target enrollment:** 390 (ESTIMATED)
- **Last updated:** 2025-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05335928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05335928, "Abatacept in Immune Checkpoint Inhibitor Myocarditis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05335928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*